Physician profile
Taylor C Bear
NPI 1801019617
$56,184.33
in general payments reported to CMS, 2019-2025
79 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,280 · 2020: $5,211 · 2021: $17K · 2022: $13K · 2023: $4,206 · 2024: $4,394 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Consulting Fee: $5,000 · Travel and Lodging: $1,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,065.63 |
| Consulting Fee | $5,000.00 |
| Travel and Lodging | $1,204.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $14,091.52 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $7,238.49 | 2022 | |
| Pfizer INC. | $5,823.68 | 2021-2025 | |
| Abbvie INC. | $2,592.57 | 2020-2025 | Qulipta, Botox, Ubrelvy |
| Ucb, INC. | $2,004.56 | 2019-2025 | Fintepla, Briviact, Rystiggo |
| Mdd US Operations, LLC | $1,784.90 | 2019-2025 | Gocovri, Gocovri |
| Livanova USA, INC. | $1,775.64 | 2024-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Emd Serono, INC. | $1,652.38 | 2019-2025 | Mavenclad |
| Biogen, INC. | $1,460.11 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Eisai INC. | $1,155.38 | 2019-2025 | |
| Neurelis, INC. | $1,042.46 | 2020-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $1,023.65 | 2019-2025 | Ultomiris, Soliris |
| Acadia Pharmaceuticals INC | $900.56 | 2019-2025 | Nuplazid |
| Novartis Pharmaceuticals Corporation | $879.44 | 2019-2025 | |
| Lundbeck LLC | $860.17 | 2020-2025 | Vyepti, Rexulti |
Show all 79 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $795.61 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $770.48 | 2020-2025 | Ingrezza, Ongentys |
| Argenx US, INC. | $674.68 | 2022-2025 | Vyvgart Hytrulo |
| Teva Pharmaceuticals USA, INC. | $593.38 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Celgene Corporation | $566.32 | 2020-2025 | Zeposia |
| Lilly USA, LLC | $562.03 | 2020-2025 | Amyvid, Kisunla, Emgality |
| Csl Behring | $473.21 | 2019-2024 | Hizentra |
| Allergan, INC. | $450.79 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $432.58 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $381.74 | 2022-2025 | Epidiolex |
| Kyowa Kirin, INC. | $354.44 | 2021-2024 | Nourianz |
| Sk Life Science, INC. | $325.53 | 2020-2025 | Xcopri |
| Astrazeneca Pharmaceuticals LP | $320.99 | 2021-2025 | Wainua, Andexxa |
| Greenwich Biosciences, INC. | $310.18 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $286.35 | 2021-2023 | Ponvory |
| Supernus Pharmaceuticals, INC. | $275.27 | 2019-2024 | Qelbree |
| Amneal Pharmaceuticals LLC | $265.91 | 2020-2025 | Crexont, Rytary |
| Genzyme Corporation | $258.12 | 2019-2025 | |
| Amgen INC. | $255.17 | 2019-2024 | Aimovig, Uplizna |
| E.R. Squibb & Sons, L.L.C. | $230.94 | 2020-2021 | |
| Adamas Pharmaceuticals, INC. | $226.23 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $212.47 | 2023-2024 | Aptiom |
| Arbor Pharmaceuticals, INC. | $211.04 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $198.72 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $183.57 | 2022-2025 | Fycompa |
| Otsuka America Pharmaceutical, INC. | $164.60 | 2023-2025 | Nuedexta |
| Tg Therapeutics, INC. | $164.24 | 2023-2025 | |
| Genentech USA, INC. | $157.07 | 2021-2024 | Ocrevus, Ocrevus Zunovo |
| Banner Life Sciences, LLC | $155.04 | 2022-2024 | |
| Boston Scientific Corporation | $104.77 | 2020-2025 | Wavewriter Alpha Prime 16 |
| Alnylam Pharmaceuticals INC. | $104.05 | 2020-2022 | |
| Corium, LLC | $102.13 | 2022-2023 | Adlarity |
| Ani Pharmaceuticals, INC. | $95.66 | 2022-2023 | Purified Cortrophin Gel |
| Tanabe Pharma America, INC. | $93.78 | 2021-2022 | |
| Acorda Therapeutics, INC | $93.22 | 2019-2022 | |
| Octapharma USA, INC. | $84.58 | 2023-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Cycle Pharmaceuticals INC | $74.64 | 2024-2025 | Tascenso Odt, Bafiertam |
| Impel Pharmaceuticals INC. | $65.40 | 2023 | Trudhesa |
| Janssen Biotech, INC. | $62.10 | 2025 | |
| Mallinckrodt Hospital Products INC. | $61.10 | 2025 | Acthar |
| Merz North America, INC. | $60.31 | 2019 | |
| Abbott Laboratories | $57.77 | 2025 | Infinity |
| Axsome Therapeutics, INC. | $54.50 | 2025 | Symbravo |
| Scilex Pharmaceuticals INC. | $53.10 | 2023-2025 | Ztlido |
| Takeda Pharmaceuticals U.S.A., INC. | $49.22 | 2023-2024 | Hyqvia |
| Promius Pharma LLC | $48.86 | 2019 | |
| Grifols USA, LLC | $39.93 | 2020-2025 | Gamunex-C |
| Almatica Pharma LLC | $34.60 | 2021-2022 | |
| Mallinckrodt Enterprises LLC | $29.64 | 2019 | |
| Vanda Pharmaceuticals INC. | $29.58 | 2024-2025 | Ponvory |
| Biotronik INC. | $27.90 | 2021 | |
| Medtronic, INC. | $25.43 | 2024 | Intellis Adaptivestim |
| Horizon Therapeutics Plc | $23.69 | 2022 | |
| Amylyx Pharmaceuticals, INC. | $21.35 | 2024 | Relyvrio |
| Xeris Pharmaceuticals, INC. | $18.35 | 2022 | |
| Impel Pharmaceuticals LLC | $16.65 | 2025 | Trudhesa |
| Nevro Corp. | $15.69 | 2023 | Senza |
| Sandoz INC. | $15.16 | 2023 | |
| Currax Pharmaceuticals LLC | $14.96 | 2020 | |
| Avion Pharmaceuticals | $13.97 | 2022 | |
| Merz Pharmaceuticals, LLC | $13.92 | 2025 | Xeomin |
| Zyla Life Sciences, INC. | $12.47 | 2019 | |
| Merck Sharp & Dohme LLC | $12.12 | 2020 | |
| Novo Nordisk INC | $11.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$37,411.40 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Bear listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.